This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of ptosis secondary to myasthenia gravis.
The rationale behind using Apraclonidine is that it acts on Muller's muscle which is a sympathetic-innervated muscle. As such, this muscle is expected to be spared from the effects of the autoantibodies that attack the postsynaptic portion of the neuromuscular junction in myasthenia gravis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
American University of Beirut Medical Center
Beirut, Lebanon
Change in palpebral fissure height (PF)
Change in PF measurements
Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration
Change in marginal reflex distance-1 (MRD1)
Change in MRD1 measurements
Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration
Change in marginal reflex distance-2 (MRD2)
Change in MRD2 measurements
Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration
Change in levator function (LF)
Change in LF measurements
Time frame: Before administration, at 1, 5, 30, and 60 minutes after administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.